Home › The Protocol Vault › Cytoflavin

Cytoflavin

Succinic acid + inosine + nicotinamide + riboflavin — a Russian metabolic combination

Performance & EnduranceOral✅ Clinically validated

Cytoflavin (Succinic acid + inosine + nicotinamide + riboflavin — a Russian metabolic combination) is a performance & endurance research compound. Four ingredients that sit in one stretch of mitochondrial metabolism: succinic acid feeds electrons directly into complex II, inosine regenerates adenine nucleotides, nicotinamide is the NAD precursor and riboflavin the FAD precursor. That is a more coherent rationale than most combination products manage. It also runs into a problem inside its own lead ingredient — succinate accumulation is what the modern reperfusion-injury literature identifies as the driver of the reactive oxygen species burst when blood returns to ischemic tissue. Fuel and trigger are the same molecule at the same enzyme; which description applies depends on the oxygen state of the tissue.

Research & educational use only. The information below summarizes published research and mechanisms. It is not medical advice or a recommendation for human use. The protocol that uses it — dosing, sequence and what to retest — is inside Skool ($10/mo).

Cytoflavin quick facts

RouteOral
FrequencyNot established for the oral form alone · Not established
Half-lifeNo published pharmacokinetics for the finished product — no plasma curve, no bioavailability figure, no half-life
FormsOral
Evidence levelOne randomized double-blind placebo-controlled trial in diabetic neuropathy (n=216) which began intravenously; one uncontrolled athlete study.
Coach Cam’s take

There is a real randomized placebo-controlled trial behind this, and the regimen it tested is not the one a tablet buyer runs: 10 days intravenous, then 75 days oral, in 216 people with diabetic neuropathy. The symptom score difference was 0.92 points on a subjective scale, and the authors list a small effect size and subjective outcome assessment among their own limitations. The athlete study everyone quotes had no randomization, no blinding and no placebo — and read it carefully, because the untreated group lost weight faster than the treated one and the paper presents that as a benefit. Nobody has measured uric acid on it, which is the marker inosine should move.

How Cytoflavin works

Four ingredients that sit in one stretch of mitochondrial metabolism: succinic acid feeds electrons directly into complex II, inosine regenerates adenine nucleotides, nicotinamide is the NAD precursor and riboflavin the FAD precursor. That is a more coherent rationale than most combination products manage. It also runs into a problem inside its own lead ingredient — succinate accumulation is what the modern reperfusion-injury literature identifies as the driver of the reactive oxygen species burst when blood returns to ischemic tissue. Fuel and trigger are the same molecule at the same enzyme; which description applies depends on the oxygen state of the tissue.

Where to get Cytoflavin

Buy Cytoflavin at RUPharma →
Use code CAMERON at checkout

The evidence for Cytoflavin

Graded by what exists behind each claim.

✅ Clinically validated

📊 Correlative data

🧪 Theoretical / extrapolated

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Cytoflavin actually does

Four ingredients, and the argument is that they sit in one pathway. Cytoflavin is succinic acid (as meglumine sodium succinate), inosine, nicotinamide and riboflavin. Read as biochemistry rather than as a supplement blend, that is: a tricarboxylic acid cycle intermediate that feeds electrons straight into complex II, a purine that regenerates adenine nucleotides, the precursor of NAD, and the precursor of FAD. Every one of the four is a substrate or a cofactor for the same stretch of mitochondrial metabolism, which is a more coherent rationale than most combination products manage.

The mechanistic problem sits inside the lead ingredient. Chouchani 2014 showed that succinate accumulation during ischemia is what drives reperfusion injury — on reoxygenation the accumulated succinate is rapidly oxidized at complex II, driving reverse electron transport and a burst of mitochondrial reactive oxygen species. That is the modern account of why ischemic tissue is damaged when blood returns, and its central actor is the molecule this product supplies. The developers argue succinate as fuel; the reperfusion literature treats it as the trigger. Both descriptions are of the same molecule at complex II, and which one applies depends entirely on the oxygen situation of the tissue at the time.

What the animal work found, and it undercuts the marketing rather than supporting it. Volchegorskii 2013 gave cytoflavin and its separate components to mice under acute alloxan intoxication. The components with in vitro antioxidant activity — riboflavin, inosine and nicotinamide — reduced the hyperglycemic effect. But the protection against behavioral disruption traced to meglumine sodium succinate and inosine, and the authors state it did not depend on their influence on free-radical oxidation. The product is sold as an antioxidant. Its own component study says the antioxidant activity is not what produced the protective effect it measured.

What is in the box. A partner lists it at $25 in more than one presentation, because the product exists as both an intravenous solution and a tablet. That distinction is not cosmetic and the next section is mostly about it.

Cell, rodent, human — and where it stops

There is a real randomized placebo-controlled trial, and the regimen it tested is not the one a tablet buyer will run. Kharitonova 2022 enrolled men and women aged 45 to 74 with type 2 diabetes and symptomatic diabetic polyneuropathy, Total Symptom Score at least 5, randomized 109 to the combination and 107 to placebo. The medication was given intravenously for 10 days and then orally for 75 days. Anyone buying tablets is buying the second phase of a two-phase protocol whose first phase was an intravenous loading course, and no arm of that trial tested oral dosing alone.

The result, with the number the abstract leads on and the number that matters. Mean Total Symptom Score change at 12 weeks was -2.65 against -1.73 on placebo, p<0.0001 Kharitonova 2022. The p-value is emphatic. The between-group difference is 0.92 points on a subjective symptom scale, and the authors themselves list among their study's limitations a small effect size and subjective assessment of outcomes. A trial that reports its own effect as small is being more careful than most, and quoting its p-value without its effect size would be the standard misuse of it.

The athlete study is the one this readership will find, and it is much weaker. Zaborova 2023 gave the drug to 30 professional male ice hockey players aged 19 to 36 for six weeks and compared them with 30 who received nothing. No randomization, no blinding and no placebo appear in the abstract. Read the body composition result carefully: in the treated group, reductions in body weight and body mass index were not observed until day 14 and day 35, while in the untreated group both fell significantly at both time points. The control group lost weight faster, and the paper presents this as improved control of weight reduction. Aerobic performance rose in both groups, more in the treated one.

Where the class sits, and what a sport reader should know. Jędrejko 2024 reviews this product alongside Mexidol and other succinate derivatives as antihypoxic and anti-ischemic metabolic modulators and as ergogenic aids in athletes, and explicitly considers their potential as performance-enhancing drugs. Yagudina 2019 places it inside the Russian neuroprotective market for ischemic stroke, which is the clinical context this product was built for and the one furthest from a healthy person taking it for energy.

Cytoflavin pharmacokinetics — how much of it actually gets in

The route difference is the pharmacokinetics, and the trial chose the harder route first for a reason. Succinate is a dicarboxylic anion at physiological pH. Charged dicarboxylates do not diffuse across membranes; they move on sodium-dependent dicarboxylate transporters, which are saturable and concentrated in kidney and gut rather than distributed for delivery. An intravenous dose skips that problem entirely. That is the most plausible reason Kharitonova 2022 began with 10 days intravenous before switching to 75 days oral, and it is the reason a tablet cannot inherit the trial's result unexamined.

Three of the four ingredients have well-characterized oral handling and none of it is dramatic. Riboflavin absorption is carrier-mediated and saturates in the low tens of milligrams per dose, so a larger tablet does not produce a proportionally larger exposure — the visible consequence is bright yellow urine, which is unabsorbed vitamin leaving. Nicotinamide is well absorbed and feeds the NAD salvage pathway. Inosine is largely deaminated in the gut wall and liver to hypoxanthine and ends up as urate, which is the single most useful pharmacokinetic fact on this page and the safety section returns to it.

No published human pharmacokinetic study of the finished product exists. There is no reported plasma curve for the combination, no oral bioavailability figure, no half-life for the formulation and no comparison of the tablet against the infusion. Kharitonova 2022 is a clinical endpoint trial and reports no concentrations. So the honest position is that the product has an outcome measurement and no exposure measurement, and the two cannot be connected.

What that implies for a dose taken around training. Succinate's own plasma concentration rises during intense exercise from muscle metabolism, without any being swallowed. Nobody has published whether an oral dose adds measurably to that, and until somebody does, the timing advice attached to this product in the sports market is inference on top of an unmeasured exposure.

What would have to be true, and how you would know it was not

Three predictions, and the third is the one that would settle the product's central question.

1. Uric acid, before and after a course. Inosine is a purine and its metabolic end point in humans is urate. Prediction: serum uric acid rises. It is a standard, cheap, widely ordered test; it is the marker most likely to move on this product; and no published study of the combination reports it. This is both a falsification of the pharmacology and the most likely route to a real adverse effect.

2. Fasting glucose and HbA1c, in anyone using it for the reason the trial studied. Kharitonova 2022 reports that symptom reduction occurred regardless of HbA1c, which means the drug was not working by improving glycemic control. Prediction: HbA1c unchanged. If it moves, the effect being attributed to the drug belongs to something else in the protocol.

3. Against the product: a submaximal VO2 test, before and after six weeks of tablets alone. The athlete study reported greater aerobic improvement in the treated group without randomization, blinding or a placebo Zaborova 2023, in a squad in preseason training. Prediction: with a placebo arm and oral dosing only, the difference disappears. That trial has never been run, and it is a twelve-week study with sixty athletes and one gas analyzer.

What nobody has tested yet

Nobody has tested the tablet without the infusion. The one good randomized trial used 10 days intravenous then 75 days oral Kharitonova 2022, and no arm isolated the oral phase. Since the vendor sells the tablet and the trial is what justifies the tablet, that missing arm is the single most consequential gap on the page, and it would take one three-arm study to close.

Nobody has resolved which ingredient does the work. Volchegorskii 2013 is the only study that took the combination apart, in mice, and it found the behavioral protection traced to succinate and inosine while the antioxidant effect traced elsewhere and did not explain the protection. A four-ingredient product with one component-level animal study and no component-level human study is a blend, not a molecule, and it cannot be graded like one.

Nobody has measured urate on it. Inosine's purine metabolism is textbook, the trial ran 85 days Kharitonova 2022, and a serum uric acid costs almost nothing. It appears in no abstract in this literature. That is not a hard experiment; it is an omission.

Extrapolation, labeled as such. If the mechanism really runs through complex II, then three things follow that nobody has looked for: the effect should be larger in tissue that is hypoxic rather than well oxygenated, which is testable by comparing altitude with sea level; it should be reduced by a complex II inhibitor; and it should be absent where succinate is already elevated by exercise Chouchani 2014. The last of those is the awkward one for a sports claim, because a hard interval session already raises the molecule the tablet is supplying.

Cytoflavin — its own safety story, not its class's

Three things this combination owns that a generic blend warning does not cover.

The purine load is the concrete risk and nobody publishes it. Inosine is metabolized to hypoxanthine and then to uric acid. For most people that is unremarkable; for somebody with gout, a history of urate kidney stones, or a uric acid already sitting at the top of the range, a daily purine load for 75 days Kharitonova 2022 is a foreseeable way to provoke an attack. No study in this literature reports serum urate, so the size of the effect is unknown rather than reassuring.

The sport-testing position is not settled and should not be assumed. Jędrejko 2024 reviews this product and its chemical relatives specifically in the context of their potential as performance-enhancing drugs. Nothing here says it is prohibited. What it says is that a competing athlete should check the current prohibited list and monitoring program for themselves rather than assume that four metabolites make an unregulated product.

And an intravenous product bought online is a different risk class from a tablet. This is sold in more than one form. The clinical evidence was generated with an infusion given in a hospital over ten days, and the version of that a person can replicate at home involves sterile technique, an intact vein and a product whose manufacturing nobody in this chain has inspected. The tablet's unknowns are pharmacological. The ampoule's unknowns include infection, and that is a different conversation.

Sources read for this page

Cytoflavin — interference & stacking

Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →

What Cytoflavin moves on your bloodwork

Expected direction, not a measured one.

This class is where honest expectation-setting matters most: the markers above are how you find out whether anything happened, and for most of these compounds that question is genuinely open.

🔒
The dose is the easy part. Making Cytoflavin actually work is what's behind Skool:
Running it
  • Dose range and how to work up to it
  • When to take it, and why that window
  • Cycle length
  • Time off between cycles
  • Fasted or fed, and when in the day
  • Coach Cam's personal notes
Stacking it
  • Which compounds push the same lever, and why the dose adds up faster than people count
  • What blunts it — the stacks that waste your money
  • What compounds the risk, so a side effect arrives sooner than any one of them suggests
  • Coach Cam's read on running it alongside the rest of your protocol

Everything above is free and stays free. Skool is where it becomes a plan — Cytoflavin in an order, with the rest of what you're running.

Unlock in Skool — $10/mo →

Bloodwork to run alongside Cytoflavin

Baseline first, then again at 8–12 weeks.

MarkerWhat it’s watching for
Comprehensive Metabolic Panel (CMP)Liver, kidney, electrolytes and glucose in one
Complete Blood Count (CBC) with DifferentialBroad screen for anything unexpected
hs-CRP (High-Sensitivity C-Reactive Protein)Inflammation baseline

The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.

Check results you already have → · All 103 markers A–Z

Cytoflavin — frequently asked questions

What is Cytoflavin?

Cytoflavin (Succinic acid + inosine + nicotinamide + riboflavin — a Russian metabolic combination) is a performance & endurance research compound. Four ingredients that sit in one stretch of mitochondrial metabolism: succinic acid feeds electrons directly into complex II, inosine regenerates adenine nucleotides, nicotinamide is the NAD precursor and riboflavin the FAD precursor. That is a more coherent rationale than most combination products manage. It also runs into a problem inside its own lead ingredient — succinate accumulation is what the modern reperfusion-injury literature identifies as the driver of the reactive oxygen species burst when blood returns to ischemic tissue. Fuel and trigger are the same molecule at the same enzyme; which description applies depends on the oxygen state of the tissue.

Where can I find Cytoflavin dosing and protocols?

Dosing, the reconstitution calculator and Coach Cam's full Cytoflavin protocol are available to members inside Skool. This public page covers what Cytoflavin is, how it works and the evidence.

What is the half-life of Cytoflavin?

Cytoflavin has an approximate half-life of No published pharmacokinetics for the finished product — no plasma curve, no bioavailability figure, no half-life, which is part of what determines how often it's dosed.

What's the evidence behind Cytoflavin?

Current evidence level: One randomized double-blind placebo-controlled trial in diabetic neuropathy (n=216) which began intravenously; one uncontrolled athlete study.. Cytoflavin is offered for research purposes only and is not an approved medicine.

What Cytoflavin is used for

Cytoflavin appears under 1 goal in the goal router.

🏃 Endurance & work capacitySubstrate & fuel availability
BemethylHypoxenRoxadustat

Where this goes next

In contextSubstrate & fuel availabilityThe endurance & work capacity pathway Cytoflavin belongs to
Go deeper$10/mo

The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.

Every protocol on the site

← Explore the full Protocol Vault

↑ Back to on this page